Targeted IDH1 inhibitor takes on advanced solid tumors
NCT ID NCT07738679
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This phase II trial evaluates TQB3454, an oral drug that targets a specific genetic mutation (IDH1) found in some solid tumors. The study enrolls adults with advanced solid tumors, including glioma, other IDH1-mutated cancers, and biliary tract cancer without the mutation. Participants receive TQB3454 as a single treatment, and researchers measure how well it controls tumor growth and its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TQB3454 tablets, a selective inhibitor of the IDH1 mutant enzyme
- What this could lead to
- If successful, TQB3454 could offer a new targeted treatment option for people with advanced solid tumors that have specific IDH1 mutations, potentially slowing disease progression.
- What could go wrong
- This is a phase II trial, so the drug may not prove effective or safe in a larger population. Side effects are possible, and the benefit may vary among different tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AnYang Tumor Hospital
Anyang, Henan, 455001, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, 210029, China
-
Liaoning Tumor Hospital & Institute
Shenyang, Liaoning, 110044, China
-
Luoyang Central Hospital (Zhengzhou University Affiliated Luoyang Central Hospital)
Luoyang, Henan, 471000, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 101109, China
-
Sanbo Brain Hospital,Capital Medical University
Beijing, Beijing Municipality, 100018, China
-
Shandong Cancer Hosipital
Jinan, Shandong, 250117, China
-
Shanghai Sixth People's Hospital, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, 200233, China
-
SiChuan cancer hospital
Chengdu, Sichuan, 610041, China
-
Sun Yat-Sen Uuniversity Cancer Cerntr
Guangzhou, Guangdong, 510000, China
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221004, China
-
The First Affiliated Hospital of Xi 'an Jiaotong University Medical College
Xi'an, Shaanxi, 710000, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130033, China
-
The Second Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, 710000, China
-
The Second Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, 710000, China
-
The Second Hospital & Clinical Medical School, Lanzhou University
Lanzhou, Gansu, 730030, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, 100032, China
-
Zhengzhou University First Affiliated Hospital
Zhengzhou, Henan, 45002, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.